IGC Pharma, Inc.

NYSEAM:IGC Stock Report

Market Cap: US$32.7m

IGC Pharma Management

Management criteria checks 4/4

IGC Pharma's CEO is Ram Mukunda, appointed in Apr 2005, has a tenure of 20.58 years. total yearly compensation is $568.00K, comprised of 69.7% salary and 30.3% bonuses, including company stock and options. directly owns 4.34% of the company’s shares, worth $1.42M. The average tenure of the management team and the board of directors is 7.5 years and 3.7 years respectively.

Key information

Ram Mukunda

Chief executive officer

US$568.0k

Total compensation

CEO salary percentage69.72%
CEO tenure20.6yrs
CEO ownership4.3%
Management average tenure7.5yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Does India Globalization Capital's (NYSEMKT:IGC) CEO Salary Compare Well With Industry Peers?

Feb 27
Does India Globalization Capital's (NYSEMKT:IGC) CEO Salary Compare Well With Industry Peers?

CEO Compensation Analysis

How has Ram Mukunda's remuneration changed compared to IGC Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$6m

Mar 31 2025US$568kUS$396k

-US$7m

Dec 31 2024n/an/a

-US$9m

Sep 30 2024n/an/a

-US$13m

Jun 30 2024n/an/a

-US$13m

Mar 31 2024US$2mUS$360k

-US$13m

Dec 31 2023n/an/a

-US$14m

Sep 30 2023n/an/a

-US$11m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023US$1mUS$360k

-US$12m

Dec 31 2022n/an/a

-US$14m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022US$6mUS$320k

-US$15m

Dec 31 2021n/an/a

-US$11m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021US$801kUS$292k

-US$9m

Dec 31 2020n/an/a

-US$9m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020US$719kUS$300k

-US$7m

Dec 31 2019n/an/a

-US$6m

Sep 30 2019n/an/a

-US$5m

Jun 30 2019n/an/a

-US$5m

Mar 31 2019US$712kUS$300k

-US$4m

Compensation vs Market: Ram's total compensation ($USD568.00K) is about average for companies of similar size in the US market ($USD582.44K).

Compensation vs Earnings: Ram's compensation has been consistent with company performance over the past year.

CEO

Ram Mukunda (66 yo)

20.6yrs
Tenure
US$568,000
Compensation

Mr. Ram Mukunda is the Founder of IGC Pharma, Inc. (formerly known as India Globalization Capital, Inc.) and has been Chief Executive Officer, President and Executive Director since April 29, 2005. He is r...

Leadership Team

NamePositionTenureCompensationOwnership
Ram Mukunda
Founder20.6yrsUS$568.00k4.34%
$ 1.4m
Claudia Grimaldi
VP, Principal Financial Officer7.5yrsUS$259.00k1.23%
$ 403.8k
Benysh Qureshi
Director of Operations1.3yrsno datano data
Rohit Goel
Director of Accounting & Senior Director8.2yrsUS$41.00kno data
Susana Salgar
Sales Managerless than a yearno datano data
7.5yrs
Average Tenure
54yo
Average Age

Experienced Management: IGC's management team is seasoned and experienced (7.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ram Mukunda
Founder20.6yrsUS$568.00k4.34%
$ 1.4m
Claudia Grimaldi
VP, Principal Financial Officer3.7yrsUS$259.00k1.23%
$ 403.8k
Richard Prins
Independent Chairman of the Board18.5yrsno data1.38%
$ 452.6k
Terry Lierman
Independent Director1.7yrsno data0.032%
$ 10.5k
Jeffrey Cummings
Scientific Advisorno datano datano data
Howard Gutman
Strategic Board Advisorless than a yearno datano data
Terry McAuliffe
Board Advisorless than a yearno datano data
James Saunders
Scientific Advisorno datano datano data
Chuanhai Cao
Scientific Advisorno datano datano data
James Moran
Independent Director3.8yrsno data1.2%
$ 393.6k
Elliot Hong
Scientific Advisorno datano datano data
Pablo Arbelaez
Scientific Advisorno datano datano data
3.7yrs
Average Tenure
68yo
Average Age

Experienced Board: IGC's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/14 22:57
End of Day Share Price 2025/11/14 00:00
Earnings2025/06/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IGC Pharma, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Edward WooAscendiant Capital Markets LLC